Import Safety Legislation: Generic Firms Could Accept Fees, Not Delays
Executive Summary
FDA's decision to invoke its Application Integrity Policy with Ranbaxy emphasizes the political risks that the generic industry faces as the debate on import safety returns the fore in Congress
You may also be interested in...
ANDA User Fees: Industry Takes Holistic Approach, Wants Whole New Office
The generics industry is pushing FDA to create a commissioner-level office dedicated to handling issues related to ANDAs during negotiations over the creation a user fee program for generic drugs
ANDA User Fees: Industry Takes Holistic Approach, Wants Whole New Office
The generics industry is pushing FDA to create a commissioner-level office dedicated to handling issues related to ANDAs during negotiations over the creation a user fee program for generic drugs
Generics Industry Faces Five Major Challenges, Actavis CEO Says (We're Partly Responsible For One Of Them, He Acknowledges)
U.S. ANDA makers are ending their silver anniversary year on a glum note